Falling knives are stocks whose share price has fallen more than 59% over the past year, drawing interest from investors as these securities can deliver huge rewards if they rebound.
The share price flop, however, could be the beginning of financial troubles, which may hurt the portfolio of an investor severely if the business goes bankrupt.
Investors can significantly reduce potential risks if they pick falling knives with moderate to low debt-equity ratios.
Together with a moderate to low financial burden, the following securities have received positive recommendation ratings on Wall Street, suggesting they are expected to outperform either their industries or the entire market.
The Cambridge, Massachusetts-based biopharmaceutical company, which focuses on developing treatments for serious diseases such as cancer and fibrosis, has a very low debt-equity ratio of 0.04 versus the industry median of 0.12.
GuruFocus assigned a rating of 5.8 out of 10 for the company's financial strength, but a very low rating of 1 out of 10 for its profitability.
The closing price on Friday was below the 200-, 100- and 50-day simple moving average lines. The 52-week range is $8.09 to $30.
The price-book ratio is 1.68 compared to the industry median of 3.25.
The 14-day relative strength index of 44 suggests the stock is still far from oversold levels.
Wall Street issued a buy recommendation rating with an average target price of $31.67.
The San Francisco-based life sciences research technologies manufacturer has a moderate debt-equity ratio of 0.35 versus the industry median of 0.27.
GuruFocus assigned a rating of 5 out of 10 for the company's financial strength, but a low rating of 2 out of 10 for its profitability.
The closing price on Friday was below the 200-, 100- and 50-day simple moving average lines. The 52-week range is $2.31 to $14.09.
The price-book ratio is 1.01 compared to the industry median of 3.65 and the price-sales ratio is 1.13 versus the industry median of 3.41.
The 14-day relative strength index of 19 suggests the stock is oversold.
Wall Street issued an overweight recommendation rating with an average target price of $8.30.
Disclosure: I have no positions in any securities mentioned.
Read more here:
- 3 Good Performers Expected to Trade Higher
- Disney Rises on 4th-Quarter Earnings Beat
- 3 High-Yield Large-Cap Stocks Beat S&P 500 Index Dividends
Not a Premium Member of GuruFocus? Sign up for aÂ free 7-day trial here.